Roche eye drug fails late-stage trial in blow to pipeline Ruby Khatun Khatun11 Sept 2017 9:32 AM ISTZURICH: A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday...
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in Immuno-Oncology Ruby Khatun Khatun9 Sept 2017 9:57 AM ISTKENILWORTH, N.J. & MUNICH: Merck, known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire...
GSK bets on pioneering cancer therapy with Adaptimmune deal Ruby Khatun Khatun9 Sept 2017 9:32 AM ISTLONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology,...
Novartis hopeful for novel heart drug, despite modest benefit Ruby Khatun Khatun28 Aug 2017 1:05 PM ISTZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection...
Europe ready to embrace first copies of biotech cancer drugs supriya kashyap kashyap17 Feb 2017 12:25 PM ISTLondon : Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan...
Bayer applies for Regorafenib authorization to treat liver cancer supriya kashyap kashyap8 Nov 2016 11:56 AM ISTGerman drugmaker Bayer said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer...